The use of the inhibitors AC-73 (for CD147) and syrosingopine (for MCT4) in the treatment of AML induces autophagy, alone or in combination with conventional chemotherapeutic agents, cytarabine (Ara-C) and all-trans-retinoic acid (ATRA), resulting effective in overcoming the chemotherapy resistance of treated AML cells [193,194]. The gene discussed is BSG; the disease is acute myeloid leukemia.